Related Experiment Videos
Antithrombotic treatment of acute coronary syndromes
1Department of Medicine, Montreal Heart Institute, University of Montreal, Quebec. theroux@icm.umontreal.ca
Insights
This review covers antithrombotic treatments for acute coronary syndromes, including thrombolytics, anticoagulants, and antiplatelet drugs. Future treatments will offer new options for managing these cardiovascular conditions.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute coronary syndromes (ACS) involve complex coagulation processes.
- Effective management requires understanding antithrombotic strategies.
Purpose of the Study:
- To review the coagulation process.
- To provide an overview of current and developing antithrombotic treatments for ACS.
Main Methods:
- Literature review of antithrombotic agents.
- Categorization of treatments into thrombolytic, anticoagulant, and antiplatelet classes.
Main Results:
- Thrombolytics are crucial for ST-elevation myocardial infarction but not other ACS.
- Anticoagulants offer acute benefits but have limitations upon discontinuation.
- Antiplatelet therapy, including acetylsalicylic acid, is beneficial across ACS phases.
- Newer anticoagulants (e.g., low molecular weight heparins) and antiplatelet agents (e.g., glycoprotein IIb/IIIa inhibitors) represent future treatment opportunities.
Conclusions:
- A range of antithrombotic agents are available for ACS management.
- Ongoing research promises enhanced therapeutic options for cardiovascular care.
Abstract:
This article provides a brief review of the coagulation process and an overview of the different antithrombotic treatment strategies that are available or being developed for the management of acute coronary syndromes. Active antithrombotic agents belong to three general classes: thrombolytic agents, anticoagulants and antiplatelet drugs. Thrombolytic agents are life-saving in acute myocardial infarction with ST segment elevation, but they are not useful and possibly harmful in other acute coronary syndromes. Anticoagulants are very effective during the acute phase, but their benefit is limited by reactivation of the disease following their discontinuation. Antiplatelet therapy with acetylsalicylic acid is useful during the acute, subacute and more chronic phases of acute coronary syndromes. The future is rich in treatment opportunities with the availability of a new generation of anticoagulants (e.g., low molecular weight heparins) and of antiplatelet agents (i.e., glycoprotein IIb/IIIa inhibitors).